Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aritech PMA

This article was originally published in The Gray Sheet

Executive Summary

Following 800-patient Protect AF clinical trial for its Watchman left atrial appendage (LAA) closure technology, company announces Aug. 18 it has filed a PMA with FDA. The LAA closure technology is designed to prevent stroke by keeping blood clots from entering the blood stream. Aritech plans to market the device as an alternative for atrial fibrillation patients who prefer not to take blood thinning medications for life. The Plymouth, Minn., firm also late year purchased left atrial appendage closure device intellectual property from ev3
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT026479

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel